<p>Larimar Therapeutics（纳斯达克代码：LRMR - 获取免费报告）在周四发布的报告中，Oppenheimer 将其目标股价从 26.00 美元下调至 21.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “跑赢大盘”。Oppenheimer 的目标价意味着该股票当前价格有 376.19% 的潜在上涨空间。</p>
<p>获取 <strong>Larimar Therapeutics</strong> 的提醒：</p>
<p>其他一些研究公司也对 LRMR 发表了看法。Guggenheim 在 6 月 24 日的研究报告中重申了对 Larimar Therapeutics 的 “买入” 评级，并设定了 26.00 美元的目标价。Robert W. Baird 在周二的研究报告中将 Larimar Therapeutics 的目标价从 10.00 美元下调至 7.00 美元，并对该公司设定了 “跑赢大盘” 的评级。花旗集团在 6 月 24 日的研究报告中重申了对 Larimar Therapeutics 的 “买入” 评级。JMP Securities 在 8 月 15 日的研究报告中将 Larimar Therapeutics 的目标价从 22.00 美元下调至 18.00 美元，并对该公司设定了 “市场跑赢大盘” 的评级。最后，Wedbush 在周二的报告中将 Larimar Therapeutics 的目标价从 15.00 美元下调至 11.00 美元，并对该股票设定了 “跑赢大盘” 的评级。根据 MarketBeat 的数据显示，九位研究分析师对该股票给予了 “买入” 评级，Larimar Therapeutics 的平均评级为 “买入”，共识目标价为 16.71 美元。</p>
<p><strong>查看我们最新的 LRMR 股票报告</strong></p>
<h2>Larimar Therapeutics 股价上涨 6.3%</h2>
<p>周四，LRMR 股票开盘价为 4.41 美元。该公司的 50 日移动平均价格为 3.90 美元，200 日移动平均价格为 2.97 美元。该股票的市值为 3.6506 亿美元，市盈率为-2.82，贝塔值为 1.00。Larimar Therapeutics 的 12 个月低点为 1.61 美元，12 个月高点为 9.50 美元。</p>
<p>Larimar Therapeutics（纳斯达克代码：LRMR - 获取免费报告）最近在 8 月 14 日公布了季度财报。该公司报告每股收益（EPS）为-0.41 美元，超出市场共识预期的-0.47 美元，超出幅度为 0.06 美元。卖方分析师预测 Larimar Therapeutics 在当前年度的每股收益将为-1.15 美元。</p>
<h2>Larimar Therapeutics 的内部活动</h2>
<p>在相关消息中，董事 James E. Flynn 在 7 月 31 日的交易中购买了 9,375,000 股该公司的股票。每股购买价格为 3.20 美元，总交易额为 30,000,000.00 美元。购买后，该董事直接持有公司 9,538,945 股股票，价值 30,524,624 美元。此次交易使其持股增加了 5,718.38%。该购买在向证券交易委员会的备案中披露，相关信息可通过此链接访问。公司内部人士持有 4.50% 的股票。</p>
<h2>对 Larimar Therapeutics 的对冲基金看法</h2>
<p>大型投资者最近买入和卖出了该公司的股票。巴黎银行金融市场在第四季度购买了 Larimar Therapeutics 的新头寸，价值约 25,000 美元。Savant Capital LLC 在第二季度购买了 Larimar Therapeutics 的新股份，价值约 39,000 美元。Wealth Enhancement Advisory Services LLC 在第二季度获得了 Larimar Therapeutics 的新头寸，价值 44,000 美元。Walleye Capital LLC 在第一季度购买了 Larimar Therapeutics 的新头寸，价值 37,000 美元。最后，Next Level Private LLC 在第二季度购买了 Larimar Therapeutics 的新股份，价值约 58,000 美元。对冲基金和其他机构投资者持有该公司 91.92% 的股票。</p>
<h2>Larimar Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Larimar Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于利用其新型细胞穿透肽技术平台开发稀有疾病的治疗方案。其主要产品候选药物 CTI-1601 目前正在进行针对弗里德里希共济失调的第二阶段 OLE 临床试验，这是一种罕见的、进行性且致命的遗传疾病。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Larimar Therapeutics</li>
<li>如何购买股票：初学者的逐步指南</li>
<li>商业新思维：UiPath 正在创造 AI 革命</li>
<li>3 只前景良好的金融科技股票</li>
<li>买入机会：Paychex 在抛售后发出反弹信号</li>
<li>大型股定义及如何投资</li>
<li>3 只鲜为人知的医疗保健股票，未来潜力巨大</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFJNUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFJNUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Larimar Therapeutics 吗？</h2>
<p>在考虑 Larimar Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Larimar Therapeutics 并不在名单上。</p>
<p>虽然 Larimar Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LRMR

<p>Oppenheimer 将 Larimar Therapeutics（NASDAQ:LRMR）的目标股价从 26.00 美元下调至 21.00 美元，同时维持 “跑赢大盘” 的评级。这个新目标暗示从当前股价来看，潜在上涨幅度为 376.19%。其他公司也给出了不同的评级，有些维持买入评级，有些则下调了目标价。Larimar 的股票开盘价为 4.41 美元，市值为 3.6506 亿美元。该公司专注于开发罕见疾病的治疗方案，并最近报告了好于预期的季度收益</p>

<p>Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) had its price target reduced by Oppenheimer from $26.00 to $21.00 in a report issued on Thursday,Benzinga reports. The firm currently has an &#34;outperform&#34; rating on the stock. Oppenheimer's price objective points to a potential upside of 376.19% from the stock's current price.</p>
<div class="lb-trans"><p>Larimar Therapeutics（纳斯达克代码：LRMR - 获取免费报告）在周四发布的报告中，Oppenheimer 将其目标股价从 26.00 美元下调至 21.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “跑赢大盘”。Oppenheimer 的目标价意味着该股票当前价格有 376.19% 的潜在上涨空间。</p>
</div><p>Get <strong>Larimar Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Larimar Therapeutics</strong> 的提醒：</p>
</div><p>A number of other research firms have also weighed in on LRMR. Guggenheim reiterated a &#34;buy&#34; rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Robert W. Baird decreased their price objective on shares of Larimar Therapeutics from $10.00 to $7.00 and set an &#34;outperform&#34; rating for the company in a research report on Tuesday. Citigroup reiterated a &#34;buy&#34; rating on shares of Larimar Therapeutics in a research report on Tuesday, June 24th. JMP Securities cut their target price on shares of Larimar Therapeutics from $22.00 to $18.00 and set a &#34;market outperform&#34; rating for the company in a research note on Friday, August 15th. Finally, Wedbush lowered their price objective on Larimar Therapeutics from $15.00 to $11.00 and set an &#34;outperform&#34; rating on the stock in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating, According to MarketBeat, Larimar Therapeutics has an average rating of &#34;Buy&#34; and a consensus target price of $16.71.</p>
<div class="lb-trans"><p>其他一些研究公司也对 LRMR 发表了看法。Guggenheim 在 6 月 24 日的研究报告中重申了对 Larimar Therapeutics 的 “买入” 评级，并设定了 26.00 美元的目标价。Robert W. Baird 在周二的研究报告中将 Larimar Therapeutics 的目标价从 10.00 美元下调至 7.00 美元，并对该公司设定了 “跑赢大盘” 的评级。花旗集团在 6 月 24 日的研究报告中重申了对 Larimar Therapeutics 的 “买入” 评级。JMP Securities 在 8 月 15 日的研究报告中将 Larimar Therapeutics 的目标价从 22.00 美元下调至 18.00 美元，并对该公司设定了 “市场跑赢大盘” 的评级。最后，Wedbush 在周二的报告中将 Larimar Therapeutics 的目标价从 15.00 美元下调至 11.00 美元，并对该股票设定了 “跑赢大盘” 的评级。根据 MarketBeat 的数据显示，九位研究分析师对该股票给予了 “买入” 评级，Larimar Therapeutics 的平均评级为 “买入”，共识目标价为 16.71 美元。</p>
</div><p><strong>View Our Latest Stock Report on LRMR</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LRMR 股票报告</strong></p>
</div><h2>Larimar Therapeutics Trading Up 6.3%</h2>
<div class="lb-trans"><h2>Larimar Therapeutics 股价上涨 6.3%</h2>
</div><p>LRMR stock opened at $4.41 on Thursday. The company has a 50-day moving average price of $3.90 and a 200 day moving average price of $2.97. The stock has a market cap of $365.06 million, a PE ratio of -2.82 and a beta of 1.00. Larimar Therapeutics has a 12 month low of $1.61 and a 12 month high of $9.50.</p>
<div class="lb-trans"><p>周四，LRMR 股票开盘价为 4.41 美元。该公司的 50 日移动平均价格为 3.90 美元，200 日移动平均价格为 2.97 美元。该股票的市值为 3.6506 亿美元，市盈率为-2.82，贝塔值为 1.00。Larimar Therapeutics 的 12 个月低点为 1.61 美元，12 个月高点为 9.50 美元。</p>
</div><p>Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.06. Sell-side analysts forecast that Larimar Therapeutics will post -1.15 EPS for the current year.</p>
<div class="lb-trans"><p>Larimar Therapeutics（纳斯达克代码：LRMR - 获取免费报告）最近在 8 月 14 日公布了季度财报。该公司报告每股收益（EPS）为-0.41 美元，超出市场共识预期的-0.47 美元，超出幅度为 0.06 美元。卖方分析师预测 Larimar Therapeutics 在当前年度的每股收益将为-1.15 美元。</p>
</div><h2>Insider Activity at Larimar Therapeutics</h2>
<div class="lb-trans"><h2>Larimar Therapeutics 的内部活动</h2>
</div><p>In related news, Director James E. Flynn purchased 9,375,000 shares of the business's stock in a transaction that occurred on Thursday, July 31st. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $30,000,000.00. Following the purchase, the director directly owned 9,538,945 shares of the company's stock, valued at $30,524,624. The trade was a 5,718.38% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. 4.50% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 James E. Flynn 在 7 月 31 日的交易中购买了 9,375,000 股该公司的股票。每股购买价格为 3.20 美元，总交易额为 30,000,000.00 美元。购买后，该董事直接持有公司 9,538,945 股股票，价值 30,524,624 美元。此次交易使其持股增加了 5,718.38%。该购买在向证券交易委员会的备案中披露，相关信息可通过此链接访问。公司内部人士持有 4.50% 的股票。</p>
</div><h2>Hedge Funds Weigh In On Larimar Therapeutics</h2>
<div class="lb-trans"><h2>对 Larimar Therapeutics 的对冲基金看法</h2>
</div><p>Large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in Larimar Therapeutics during the fourth quarter worth about $25,000. Savant Capital LLC purchased a new stake in shares of Larimar Therapeutics in the second quarter valued at approximately $39,000. Wealth Enhancement Advisory Services LLC acquired a new position in Larimar Therapeutics during the second quarter worth $44,000. Walleye Capital LLC purchased a new position in Larimar Therapeutics in the first quarter worth $37,000. Finally, Next Level Private LLC purchased a new stake in shares of Larimar Therapeutics in the 2nd quarter worth about $58,000. Hedge funds and other institutional investors own 91.92% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。巴黎银行金融市场在第四季度购买了 Larimar Therapeutics 的新头寸，价值约 25,000 美元。Savant Capital LLC 在第二季度购买了 Larimar Therapeutics 的新股份，价值约 39,000 美元。Wealth Enhancement Advisory Services LLC 在第二季度获得了 Larimar Therapeutics 的新头寸，价值 44,000 美元。Walleye Capital LLC 在第一季度购买了 Larimar Therapeutics 的新头寸，价值 37,000 美元。最后，Next Level Private LLC 在第二季度购买了 Larimar Therapeutics 的新股份，价值约 58,000 美元。对冲基金和其他机构投资者持有该公司 91.92% 的股票。</p>
</div><h2>Larimar Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Larimar Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.</p>
<div class="lb-trans"><p>Larimar Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于利用其新型细胞穿透肽技术平台开发稀有疾病的治疗方案。其主要产品候选药物 CTI-1601 目前正在进行针对弗里德里希共济失调的第二阶段 OLE 临床试验，这是一种罕见的、进行性且致命的遗传疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Larimar Therapeutics</li>
<li>How to buy stock: A step-by-step guide for beginners</li>
<li>The New Brain of Business: UiPath Is Creating an AI Revolution</li>
<li>3 Fintech Stocks With Good 2021 Prospects</li>
<li>Buy The Dip Opportunity: Paychex Signals Rebound After Sell-Off</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>3 Lesser-Known Healthcare Names With Major Upside in Store</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Larimar Therapeutics</li>
<li>如何购买股票：初学者的逐步指南</li>
<li>商业新思维：UiPath 正在创造 AI 革命</li>
<li>3 只前景良好的金融科技股票</li>
<li>买入机会：Paychex 在抛售后发出反弹信号</li>
<li>大型股定义及如何投资</li>
<li>3 只鲜为人知的医疗保健股票，未来潜力巨大</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFJNUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=LRMR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Larimar Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Larimar Therapeutics 吗？</h2>
</div><p>Before you consider Larimar Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Larimar Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Larimar Therapeutics 并不在名单上。</p>
</div><p>While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Larimar Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oppenheimer 的分析师将 Larimar Therapeutics（NASDAQ:LRMR）的目标价下调至 21.00 美元